New fluorescent tools to evaluate the therapeutic potential of phytocannabinoids
Cannabinoid receptors, CB1 and CB2 are two extensively studied targets of the GPCR family for the treatment of numerous conditions, including inflammatory diseases, autoimmune disorders, pain, and cancer.
Cannabis sativa L. has gained interest because, apart from Δ9-THC and CBD, as there are other compounds that are bioactive, by interacting with cannabinoid receptors and/or interacting with a variety of other GPCRs, e.g. GPR18, GPR55.
Thanks to the use of innovative receptor binding technologies designed by Celtarys, CELT-335 and CELT-331, it was possible to characterize through whole cell direct signalling pathways studies, new pharmacological properties derived from the action of Δ9-tetrahydrocannabinolic acid (Δ9-THCA) and Δ9- tetrahydrocannabivarin (Δ9-THCV) on CB1R, CB2R and CB1-CB2Hets.
